Welcome to our dedicated page for Venus Concept news (Ticker: VERO), a resource for investors and traders seeking the latest updates and insights on Venus Concept stock.
Venus Concept Inc. (NASDAQ: VERO) is a pioneering leader in the global medical aesthetic market, offering advanced, minimally invasive, and non-invasive aesthetic and hair restoration technologies. The company stands out with its industry-first subscription model, designed to assist both emerging and established practices in achieving success in the competitive field of aesthetics.
Venus Concept's innovative business model provides aesthetic professionals with unparalleled benefits. These include the most comprehensive warranty program, robust marketing support, continuous clinical education, and valuable practice enhancement programs. This unique approach enables practitioners worldwide to leverage cutting-edge technologies and business solutions to elevate their services and improve the quality of life for their clients.
The company's product portfolio includes a range of advanced aesthetic systems such as Venus Versa™, Venus Legacy™, Venus Velocity™, Venus Viva™, Venus Freeze Plus™, and Venus Skin™. Additionally, Venus Concept provides innovative hair restoration systems like NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. These products address various medical aesthetic needs, including skin rejuvenation, body contouring, hair restoration, and cellulite reduction.
Headquartered in Toronto, Venus Concept operates in over 60 countries and maintains a direct presence in 12 markets, ensuring a global reach and local expertise. The company's latest advancements include the Venus Bliss MAX, a multifunctional platform offering diode laser applicators, Multi-Polar Radio Frequency, and Pulsed Electromagnetic Fields, all designed to treat a variety of aesthetic concerns.
Financially, Venus Concept continues to navigate its growth trajectory with strategic partnerships and investments. The company recently underwent significant debt restructuring, supported by Madryn Asset Management, which aims to enhance its financial stability and compliance with NASDAQ listing requirements. This support underscores a commitment to achieving sustainable profitability and operational efficiency.
Venus Concept's growth is also marked by its continuous expansion into new markets, such as Australia and Israel, where its products like the Venus Versa Pro and Venus Bliss MAX have been well received. These expansions are part of the company's broader strategy to extend its technological innovations to a global clientele, offering practitioners the tools they need to deliver exceptional aesthetic treatments.
Venus Concept (NASDAQ: VERO) has initiated a U.S. Investigational Device Exemption (IDE) clinical study for its Aime™ robotic platform, aimed at treating moderate to severe facial wrinkles. The study, involving up to 70 participants aged 22 to 75, will assess the safety and efficacy of Aime in a multicenter trial across four centers. Initial patient treatment has been successfully completed. The Aime technology may enhance treatment delivery and visualization, potentially positioning Venus Concept as a leader in robotic aesthetic procedures.
Venus Concept (NASDAQ: VERO) has announced that it will release its first quarter fiscal year 2022 financial results on May 12, 2022, after market close. A conference call to discuss these results will take place at 5:00 p.m. Eastern Time, including a question and answer session for participants. Interested parties can join the call via phone or through a live webcast on the company's investor relations website.
This release marks an important date for investors looking to understand the company's performance in the competitive medical aesthetic technology market.
Venus Concept (NASDAQ: VERO) announced the submission of a 510(k) premarket notification to the FDA for its Aime™ robotic technology, aimed at tissue excision and skin resurfacing. This is a significant milestone as it marks the company's efforts to secure FDA clearance for innovative non-surgical treatments. CEO Domenic Serafino expressed optimism about Aime's potential to revolutionize medical aesthetics and aims for a U.S. commercial launch by Q4 2022. Venus Concept is recognized for its advanced aesthetic and hair restoration solutions across over 60 countries.
Venus Concept (NASDAQ: VERO) reported Q4 2021 revenue of $32.6 million, marking a 26% increase year-over-year. U.S. revenue surged 42% to $16.5 million, driven by strong system adoption, particularly for Venus Bliss and hair restoration products. Gross margin improved to 70%, up 5.3% percentage points. The operating loss decreased by 60% to $4.1 million, while net loss reduced 70% to $4.3 million. For 2022, management projects revenue growth of 20% to 23%, targeting $126 million to $130 million in total revenue.
Venus Concept, a global leader in medical aesthetic technology and listed on NASDAQ under VERO, announced its participation in the Maxim Virtual Growth Conference from March 28th to 30th, 2022. Management will deliver an on-demand presentation starting March 28th. Additionally, they will engage in a panel discussion titled 'Aesthetic Device Industry Panel' on March 28th at 1:00 PM Eastern time. Interested participants can register for the event and access the presentations via Maxim's M-Vest website.
Venus Concept, a leader in medical aesthetic technology, announced its participation in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The management will engage in a virtual fireside chat on February 16, 2022, at 11:00 a.m. ET. The webcast will be accessible to BTIG clients attending the event. Venus Concept offers a diverse product range, including aesthetic devices and hair restoration technologies, and operates in over 60 countries. Notable backers include EW Healthcare Partners and HealthQuest Capital.
Venus Concept (NASDAQ: VERO) announced its fourth quarter and fiscal year 2022 financial results will be released on March 28, 2022, before market opening. A conference call is scheduled for the same day at 8:00 a.m. ET to discuss the results, followed by a Q&A session. Participants can join via phone or through a live webcast on the investor relations website. Venus Concept specializes in minimally invasive and non-invasive medical aesthetic technologies, operating in over 60 countries with a subscription-based sales model.
Venus Concept announced FDA 510(k) clearance for its new Venus BlissMAX device, enhancing its body treatment offerings. This innovative platform combines fat reduction, cellulite treatment, and muscle conditioning in a single unit, utilizing advanced technologies like diode lasers and Multi-Polar Radio Frequency. CEO Domenic Serafino highlighted the platform's cost-effectiveness and minimal downtime for users. A limited U.S. launch is planned by Q1 2022. Venus Concept operates globally with a subscription-based sales model, serving over 60 countries.
Venus Concept reported preliminary unaudited revenue results for Q4 2021, estimating total GAAP revenue between $32.0 million and $33.0 million, up 24% to 28% year-over-year. U.S. revenues grew over 30% year-over-year, with international sales increasing 20%. Strong sales in hair restoration contributed to a 36% increase in total systems revenue. For fiscal year 2021, total GAAP revenue is expected to be between $105.0 million and $106.0 million, marking a 35% to 36% increase from 2020. Outlook for 2022 includes 20% revenue growth, driven by new product launches.
Venus Concept (NASDAQ: VERO) has successfully completed a non-brokered private placement, issuing 9,808,418 common shares and 3,790,755 preferred nonvoting shares at $1.25 each, raising approximately $17 million. The funding will support working capital and the development of AIme™, its innovative robotic technology platform. Masters Special Situations led this financing, gaining the right to nominate a director. The company anticipates achieving cash flow positivity by Q4 2022, enhancing its growth prospects in the medical aesthetics market.
FAQ
What is the current stock price of Venus Concept (VERO)?
What is the market cap of Venus Concept (VERO)?
What is Venus Concept Inc. known for?
What products does Venus Concept offer?
How does Venus Concept’s subscription model benefit practitioners?
In how many countries does Venus Concept operate?
What recent innovations has Venus Concept introduced?
What financial steps has Venus Concept taken recently?
Where is Venus Concept headquartered?
What areas do Venus Concept’s devices target?
Who are some of Venus Concept’s investors?
How does Venus Concept support its product users?
